Cellectis SA
https://www.cellectis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cellectis SA
Novartis Debuts Rapidly Manufactured Autologous CAR-Ts
The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.
From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts
Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.
Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
- Other Names / Subsidiaries
-
- Calyxt